Crystel Hajjar1*
Ed J. Kuijper2,3
Marie-José Butel4Gaelle Khoury1May Mallah1Dolla Karam Sarkis1†
Philippe Lesnik5
Wilfried Le Goff5
Ali Bazarbachi6
Marianne Abifadel1,5,7- 1Laboratory of Microbiology, Faculty of Pharmacy, Pôle Technologie-Santé, Saint Joseph University of Beirut, Beirut, Lebanon
- 2National Expertise Center for Clostridioides Difficile Infections, Leiden University Center for Infectious Diseases, Leiden, Netherlands
- 3National Institute for Public Health and the Environment, Bilthoven, Netherlands
- 4INSERM, UMR-S 1139, Physiopathologie et Pharmacotoxicologie Placentaire Humaine Microbiote Pré- et Postnatal (3PHM), Université Paris Cité, Paris, France
- 5INSERM, UMR-S 1166, Unité de Recherche sur les Maladies Cardiovasculaires et Métaboliques (ICAN), Sorbonne Université, Paris, France
- 6Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
- 7Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie-Santé, Saint Joseph University of Beirut, Beirut, Lebanon
Hematopoietic stem cell transplantation (HSCT) remains a cornerstone treatment for many hematological malignancies, but its clinical success is still challenged by graft-vs.-host disease (GvHD), infectious complications, and the profound microbial disruptions caused by conditioning, antibiotics, and hospitalization. Over the past few years, a growing body of work has highlighted how tightly post-transplant immunity is linked to the state of the gut microbiota. In particular, short-chain fatty acids (SCFAs), especially butyrate, have emerged as key microbial metabolites involved in maintaining epithelial barrier function, moderating inflammatory responses, and supporting regulatory T-cell homeostasis. In this review, we bring together current evidence on the SCFA-gut-immune axis in the setting of HSCT, with a focus on how transplant-related dysbiosis alters SCFA availability and contributes to immune imbalance. We also discuss the potential of strategies designed to restore or enhance SCFA production, ranging from dietary fiber interventions to next-generation probiotics and other microbiota-directed approaches. Overall, by better understanding and eventually harnessing the metabolic capacity of the gut microbiota, SCFA-centered therapies may offer new opportunities to support immune recovery, reduce GvHD risk, and improve outcomes for HSCT recipients. Still, well-designed clinical trials are needed to determine how these approaches can be safely and effectively integrated into transplant care.
Graphical Abstract
Introduction
Hematopoietic Stem Cell Transplantation (HSCT) is a lifesaving procedure for patients with hematological malignancies (Trunk et al., 2024). However, HSCT exerts profound and often detrimental effects on the gut microbiota. Throughout the pre-, peri-, and post-transplant phases, patients are exposed to various interventions, such as chemotherapy, radiotherapy, broad-spectrum antibiotics, and immunosuppressive therapies, that profoundly alter the gut microbial landscape (Habibi and Rashidi, 2023). This disruption leads to reduced microbial diversity and a marked depletion of beneficial short-chain fatty acid (SCFA)-producing bacteria, which are essential for maintaining gastrointestinal integrity and immune homeostasis (Habibi and Rashidi, 2023).
Microbiota injury is particularly pronounced in recipients of allogeneic HSCT, especially those who develop graft-vs.-host disease (GvHD), a major cause of morbidity and mortality following transplantation. While the broader influence of the gut microbiome on HSCT outcomes has been increasingly recognized, the specific roles and mechanisms of SCFAs in this context remain insufficiently explored (Yue et al., 2024). Although prior studies have reported alterations in microbial composition and metabolite profiles after HSCT, a focused synthesis of SCFA-mediated immunomodulatory pathways and their therapeutic potential is lacking (Riwes and Reddy, 2020).
Emerging evidence suggests that reduced SCFA levels correlate with increased immune dysregulation and more severe manifestations of GvHD (Yue et al., 2024). These observations highlight the need to better understand the SCFA-gut-immune axis in the transplant setting and to explore avenues for clinical translation.
This narrative review consolidates current evidence on SCFAs in HSCT and provides a critical perspective on their potential as therapeutic allies (Azhar Ud Din et al., 2025; Song et al., 2024). We examine:
• How HSCT alters gut microbial ecology and reduces SCFA-producing taxa;
• The immunomodulatory effects of SCFAs, including their roles in regulatory T cell induction, intestinal barrier function, and inflammation control;
• SCFA-based therapeutic strategies, ranging from diet and prebiotics to probiotics and microbial consortia, for preventing or mitigating GvHD and improving post-transplant recovery;
• And finally, we discuss future directions for integrating SCFA modulation into personalized medicine approaches in HSCT recipients.
Methodology
Search strategy and databases
This narrative review was based on a structured literature search designed to comprehensively evaluate the role of SCFAs in HSCT, with an emphasis on their immunomodulatory effects and therapeutic potential. Relevant literature was identified using PubMed and Google Scholar, covering recent articles, theses, and books.
Search terms included combinations of the following keywords: “Hematopoietic Stem Cell Transplantation (HSCT),” “Short-chain fatty acids (SCFAs),” “Gut microbiome,” “Graft-vs.-host disease (GvHD),” “Immune modulation,” and “Microbiota-directed therapy.” Boolean operators (AND, OR) were used to refine results. Manual backward and forward citation tracking of key review articles and original studies was performed to identify additional eligible sources.
Inclusion and exclusion criteria for summary tables
Studies were included in the summary tables if they met any of the following criteria:
• Investigated the role of SCFAs in HSCT recipients;
• Evaluated SCFA-targeted interventions (e.g., dietary fiber, probiotics, fecal microbiota transplantation) in clinical or preclinical HSCT contexts.
Studies were excluded if they:
• Focused on microbiome pathways unrelated to SCFAs;
• Were non-peer-reviewed sources (e.g., conference abstracts, commentaries);
• Did not report mechanistic or outcome-based data on SCFA activity in immune modulation or HSCT-related complications.
For each included study, the following data were extracted:
• SCFA levels and gut microbiota composition post-HSCT;
• Immunomodulatory effects of SCFAs on GvHD, immune reconstitution, and inflammatory pathways;
• SCFA-based therapeutic strategies involving prebiotics, probiotics, dietary interventions, or engineered microbiota.
Quality assessment and limitations
As a narrative review, no formal risk of bias assessment was conducted. However, studies were critically appraised based on:
• Study design (preclinical models, clinical trials, or observational cohorts);
• Direct relevance to SCFA metabolism, production, and immune modulation in the context of HSCT;
• Mechanistic clarity and translational potential of SCFA-driven pathways.
While this approach allows for conceptual synthesis across diverse study types, it inherently carries certain limitations:
• Risk of selection bias: Although a structured search was performed, study selection was guided by author discretion based on scientific relevance and mechanistic insight.
• Narrative synthesis limitations: The absence of meta-analytic integration precludes quantitative effect size estimation or ranking of therapeutic efficacy.
• Heterogeneity in included studies: Substantial variability exists in SCFA measurement techniques, intervention modalities, and outcome definitions across studies.
• Publication bias: Positive or preclinical findings are more likely to be published and may overrepresent the apparent benefit of SCFAs.
• Language and accessibility bias: Only English-language, publicly accessible sources were considered.
Despite these constraints, efforts were made to ensure breadth and depth of coverage, focusing on mechanistic insights and translational relevance, which are particularly valuable for hypothesis generation in this emerging field.
Hematopoietic stem cell transplantation: a lifesaving therapy with immunological risks
HSCT has emerged as a curative therapy for a range of hematological malignancies, bone marrow disorders, and inherited immune deficiencies (Riwes and Reddy, 2020; Pitea et al., 2023). This procedure involves intravenous infusion of hematopoietic stem cells obtained either from the patient (autologous) or a compatible donor (allogeneic) to reconstitute the recipient's immune system and blood-forming capacity (Khalil and Maher, 2024). While HSCT offers the potential for durable remission and long-term survival, it remains burdened by serious complications.
A principal challenge is the development of GvHD (Li et al., 2022), a potentially life-threatening condition that arises when immunocompetent donor T cells mount an alloreactive response against recipient tissues (Wang et al., 2015; Heidegger et al., 2014). GvHD may present in acute or chronic forms, with clinical manifestations affecting multiple organs including the skin, gastrointestinal tract, liver, and lungs (Vaillant et al., 2024) (Figure 1). The severity of GvHD is a critical determinant of HSCT success and patient survival (Faraci et al., 2024).
Figure 1. Schematic of the Three-Phase Pathophysiology of Graft-vs.-host disease. The development of Graft-vs.-host disease (GvHD) progresses through three distinct stages: (Phase I) Initiation of host tissue damage and cytokine release by conditioning regimens; (Phase II) Priming and clonal expansion of alloreactive donor T cells; and (Phase III) The effector phase characterized by autologous misrecognition, where activated donor T cells infiltrate and destroy host target tissues (skin, GI tract, liver, and lungs). Microbial metabolites, such as SCFAs, are critical modulators across this timeline, influencing both the initial barrier damage in Phase I and the subsequent T cell polarization in Phases II and III.
Acute GvHD (aGvHD) occurs in approximately 35–50% of allogeneic HSCT recipients, with associated mortality rates ranging from 15–20% (Bu et al., 2023). Chronic GvHD (cGvHD), which develops in 30–70% of patients, contributes significantly to long-term morbidity and is associated with mortality rates of 20–30% (Teshima et al., 2016). Risk factors influencing GvHD severity include human leukocyte antigen (HLA) disparity, conditioning intensity, and preexisting comorbidities (Dulery, 2023).
Clinically, aGvHD often presents with erythematous skin rash, gastrointestinal disturbances such as diarrhea and abdominal pain, and hepatic injury with jaundice (Malard et al., 2023a). cGvHD, in contrast, is characterized by immune-mediated tissue fibrosis and can resemble autoimmune disease, manifesting as scleroderma-like skin changes, sicca symptoms, hepatic fibrosis, and chronic pulmonary complications such as bronchiolitis obliterans (Hamilton, 2021). These complications markedly impair quality of life and may lead to irreversible organ damage, thereby impacting long-term prognosis (Vaillant et al., 2024).
The development of GvHD is classically described as a three-phase process (Zeiser and Blazar, 2017; Flowers and Martin, 2015; Jagasia et al., 2015) (Figure 1): Phase I (The Activation Phase) is initiated by the pre-transplant conditioning regimen, which damages recipient tissues and triggers the release of inflammatory cytokines and the upregulation of host histocompatibility antigens (Adams, 2024). This pro-inflammatory environment facilitates Phase II (The Expansion and Differentiation Phase), in which donor T cells recognize these host antigens as foreign. This recognition leads to the rapid clonal expansion and differentiation of donor cells into effector T cells, a process further amplified by a “cytokine storm” involving IL-2, TNF-α, and IFN-γ (Miura et al., 2002). Finally, Phase III (The Effector Phase) occurs when these activated donor cells migrate to and attack host target organs. This stage represents a state of autologous misrecognition, where the donor immune system, while technically recognizing foreign alloantigens, erroneously targets the host's healthy epithelial and stromal tissues as if they were malignant or infected, leading to the clinical manifestations of GvHD (Ferrara et al., 2009).
The gut microbiome in HSCT: a central modulator of transplant outcomes
The human gut hosts a complex and diverse community of microorganisms, including bacteria, archaea, and fungi, collectively referred to as the gut microbiota (Minagar and Jabbour, 2025). Strictly anaerobic bacteria constitute the majority of this ecosystem, deriving energy primarily through fermentation of dietary fibers and host-derived substrates, and producing key metabolic by-products such as SCFAs, carbon dioxide, hydrogen, and methane (Ríos-Covián et al., 2016). This microbial community plays a key role in host physiology by supporting nutrient metabolism, immune system maturation, and resistance to pathogen colonization (Pianko and Golob, 2022).
Among its most critical functions is the regulation of host immunity via complex, bidirectional interactions with intestinal epithelial and immune cells (Di Vincenzo et al., 2024). These dynamic microbiota-immune crosstalk mechanisms help preserve intestinal homeostasis, prevent overgrowth of opportunistic microbes, and reinforce the epithelial barrier (Hammerhøj et al., 2024). Commensal microorganisms also provide protection by competing for nutrients and adhesion sites, producing antimicrobial compounds, and supporting mucosal integrity, all contributing to reduced infection risk and balanced immune activation (Di Vincenzo et al., 2024). Additionally, the gut microbiota delivers essential developmental signals to the host immune system and facilitates energy harvest from dietary components (Yoo et al., 2020).
HSCT, while curative for many hematological malignancies and immunodeficiencies (Trunk et al., 2024), induces profound disturbances to this delicate ecosystem. Conditioning regimens (including chemotherapy and radiotherapy), broad-spectrum antibiotics, immunosuppressive therapies, mucosal damage, and nutritional alterations collectively drive a collapse in microbial diversity and function (Romick-Rosendale et al., 2018; Montassier et al., 2015; Zhao et al., 2021; Fernandes et al., 2021). A clinical study of 119 HSCT recipients linked gut microbiota changes to an increased risk of neutropenic fever, suggesting that dysbiosis may contribute to immune dysfunction during post-transplant neutropenia (Schwabkey et al., 2022). A large multicenter study of 8,767 stool samples from 1,362 patients demonstrated that lower gut microbial diversity during the peri-engraftment phase was significantly associated with increased mortality (Peled et al., 2020). Complementing this, a prospective study in pediatric recipients found that higher pre-transplant microbial diversity was associated with markedly better overall survival (88.9% vs. 62.7%) and reduced incidence of aGvHD (20.0% vs. 44.4%) (Masetti et al., 2023).
Beyond reductions in alpha diversity, recent multi-omics analyses have illuminated key functional disruptions. In a prospective cohort, Artacho et al. (2024) observed the depletion of beneficial SCFA-producing Clostridiales and associated metabolites, including butyrate, propionate, and acetate, alongside expansion of Staphylococcus and Enterococcus faecium. Notably, GvHD severity was linked to reductions in microbial genes such as superoxide reductases, underscoring the impact of metabolic and immunological impairments beyond taxonomy alone.
Colonization with multidrug-resistant organisms further exacerbates these disruptions. In a prospective study, Corcione et al. (2025) demonstrated that patients colonized with extended-spectrum β-lactamase (ESBL)-producing organisms exhibited distinct microbial profiles, with greater relative abundances of Bifidobacterium, Clostridium, Blautia, and Akkermansia. Persistent colonization was also associated with elevated rates of Clostridioides difficile infection and increased abundance of Streptococcus, a genus previously linked to aGvHD risk (Corcione et al., 2025). These findings highlight how exogenous microbial exposures modulate host-microbe dynamics and may influence post-transplant complications (Figure 2).
Figure 2. Gut microbiota balance and dysbiosis in the context of hematopoietic stem cell transplantation. The upper panel illustrates a healthy gut microbiota, in which commensal bacteria ferment dietary fiber into short-chain fatty acids (SCFAs). These metabolites are rapidly absorbed by colonocytes, serving as their primary energy source and reinforcing epithelial barrier integrity (Luu et al., 2020; Li et al., 2023). A portion of SCFAs enters the portal circulation, where they contribute to hepatic metabolic processes including lipogenesis and gluconeogenesis (Dalile et al., 2019). The lower panel depicts the post-hematopoietic stem cell transplantation (HSCT) gut, characterized by dysbiosis induced by conditioning regimens. This microbial disruption leads to a loss of SCFA-producing taxa, reduced SCFA availability, and compromised barrier function (Burgos da Silva et al., 2022). The ensuing epithelial damage facilitates bacterial translocation and triggers systemic inflammatory responses, including elevated cytokine production, which further exacerbates barrier breakdown and promotes graft-vs.-host disease (GvHD) (Ji et al., 2024; Peled et al., 2016; Rückert et al., 2022).
This HSCT-induced dysbiosis, marked by decreased microbial diversity, depletion of immunoregulatory taxa, and overrepresentation of pathobionts (Yoon and Yoon, 2018), results in a substantial reduction in critical SCFA producers such as Clostridium, Ruminococcus, Blautia, and Faecalibacterium prausnitzii (Romick-Rosendale et al., 2018; Peled et al., 2020; Burgos da Silva et al., 2022; Malard et al., 2018; Peled et al., 2018; Taur et al., 2018). One cohort study documented a significant increase in Enterococcus species post-transplant in patients who developed aGvHD (from 0.1% at baseline to 12.8%), with a concurrent decline in Enterobacteriaceae (Gavriilaki et al., 2024). Similarly, a systematic review of 10 studies comprising 490 pediatric HSCT recipients confirmed consistent reductions in microbial diversity and in SCFA-producing families, particularly Ruminococcaceae, among patients developing GvHD (Sohouli et al., 2025).
Importantly, beyond compositional changes, dysbiosis alters key host-metabolite signaling pathways. A prospective multi-omics study found that microbial disruption impairs bile acid metabolism, creating a feedback loop between intestinal microbes and immune cells that amplifies IL-1-mediated inflammation and worsens GvHD severity (Han et al., 2024).
Taken together, these studies suggest that the altered gut microbiota is not merely a bystander but a functional contributor to HSCT-associated complications, including GvHD, infections, mucositis, and graft failure. Disruption of epithelial barrier integrity, secondary to loss of commensals and expansion of proinflammatory taxa, may facilitate bacterial translocation, fueling systemic inflammation and immune dysregulation. While it remains unclear whether dysbiosis is a primary driver or a consequence of conditioning-induced immune injury, its clinical and mechanistic significance is increasingly evident (Ji et al., 2024).
Short-chain fatty acids: molecular bridges between microbiota and host immunity
SCFAs are small organic acids produced by gut microbiota through the fermentation of indigestible dietary fibers (Riwes and Reddy, 2020). The primary SCFAs in the human gut are acetate, propionate, and butyrate, which are formed at an approximate molar ratio of 60:23:17 (Romick-Rosendale et al., 2018; Haller, 2018). The production of SCFAs occurs via bacterial fermentation processes that vary across different bacterial populations in the colon. These bacteria employ distinct pathways to ferment saccharides with intermediates, such as lactate, succinate, and ethanol, which are further converted by other bacterial taxa into SCFAs (Koh et al., 2016). For instance, the major propionate producers include various Bacteroides species and Phascolarctobacterium succinatutens, whereas butyrate is predominantly produced by species such as Faecalibacterium prausnitzii and Eubacterium rectale (Koh et al., 2016; Fusco et al., 2023).
Once produced, SCFAs are absorbed by colonocytes via passive diffusion and active transport via monocarboxylate transporters (Karim et al., 2024; Rekha et al., 2024; Dalile et al., 2019). SCFAs enter the bloodstream through the colonic epithelium and are involved in systemic effects, such as metabolic processes, brain function, and osteoblast differentiation (Fock and Parnova, 2023; Abdelhalim, 2024; Boets et al., 2017; Frampton et al., 2020; Kondo et al., 2022; Mann et al., 2024; Luu et al., 2018) (Figure 2).
SCFAs have emerged as critical mediators of the gut-immune axis, exerting extensive effects on both innate and adaptive immune responses (Corrêa-Oliveira et al., 2016). The role of SCFAs in modulating immune function is multifaceted and involves their influence on the differentiation and function of immune cells, maintenance of intestinal barrier integrity, and regulation of inflammatory processes (Luu et al., 2020; Gu et al., 2021). These effects are particularly significant in the context of HSCT, where SCFAs may substantially affect patient outcomes, including the development of GvHD (Li et al., 2022; Lin et al., 2021; Markey et al., 2020).
Among SCFAs, butyrate plays an indispensable role in preserving intestinal barrier integrity, a fundamental defense against luminal antigens and pathogens (Masetti et al., 2021; Schulthess et al., 2019). As the primary energy source for colonocytes, butyrate promotes epithelial proliferation and differentiation, essential processes for maintaining a robust intestinal barrier (Ji et al., 2024; Zhang et al., 2023a). Disruption of this barrier facilitates microbial translocation triggering systemic inflammation, a key driver of GvHD pathogenesis (Di Vincenzo et al., 2024; Schulthess et al., 2019; Jansen et al., 2022; Ghosh et al., 2020). SCFAs enhance the expression of tight junction proteins such as claudin-1, occludin, and ZO-1, reducing intestinal permeability and limiting bacterial translocation (Zhang et al., 2023b; Saleri et al., 2022). Furthermore, butyrate enhances mucus production, reinforcing the epithelial defense and preventing pathogen adhesion (Chen and Vitetta, 2020).
Beyond their localized effects, SCFAs exert systemic immunomodulatory effects by influencing both the innate and adaptive immune cells. SCFAs bind to specific receptors such as free fatty acid receptors (FFARs) and histone deacetylases (HDACs), which are expressed on immune cells, thereby modulating their differentiation, activation, and function. SCFAs modulate the activity of macrophages, neutrophils, and dendritic cells, which are primary players in the innate immune response (Mann et al., 2024). Butyrate, in particular, suppresses the production of pro-inflammatory cytokines by macrophages and promotes their differentiation toward an anti-inflammatory phenotype, which is essential for mitigating inflammatory conditions such as GvHD (Chang et al., 2014; Busnelli et al., 2019). Additionally, SCFAs influence neutrophil differentiation through FFAR2 activation, affecting migration and inflammasome activity, which are critical for inflammatory responses (Liu et al., 2023; Chun et al., 2019).
In adaptive immune system, butyrate promotes regulatory T cell (Treg) differentiation, which is essential for maintaining immune tolerance and suppressing excessive immune responses (Furusawa et al., 2013). SCFAs also inhibit the differentiation and function of pro-inflammatory T helper 1 (Th1) and Th17 cells, central players in GvHD pathogenesis (Schulthess et al., 2019; Park et al., 2015; Jin et al., 2022). Their role extends on B cells, where butyrate enhances Immunoglobulin A (IgA) production, a key element in mucosal immunity (Isobe et al., 2020) (Figure 3).
The anti-inflammatory properties of SCFAs are particularly relevant in GvHD, where inflammation exacerbates tissue damage and drives clinical manifestations. SCFAs downregulate the production of key pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interferon-gamma (IFN-γ), all of which are markedly elevated in GvHD (Fujiwara et al., 2018). Furthermore, SCFAs inhibit the activation of pivotal inflammatory signaling pathways, including the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, which are implicated in GvHD pathogenesis (Kespohl et al., 2017).
Figure 3. The role of short-chain fatty acids in modulating gut immunity. Short-Chain Fatty Acids (SCFAs) are absorbed by intestinal epithelial cells via specific transporters such as MCT-1 and SMCT-1, or through passive diffusion (Corrêa-Oliveira et al., 2016). SCFAs, particularly butyrate, enhance the integrity of the intestinal barrier by promoting the expression of tight junction proteins, stimulating mucus production by goblet cells, and increasing IL-18 and antimicrobial peptide production in intestinal epithelial cells (Corrêa-Oliveira et al., 2016; Schulthess et al., 2019; Wang et al., 2024). This results in a reinforced barrier that prevents the translocation of microbial products, thereby reducing inflammation and maintaining the gut homeostasis. SCFAs modulate the activity of various innate immune cells. They promote M2 polarization of macrophages, enhancing their anti-inflammatory and phagocytic functions, including the increased production of antimicrobial peptides and LC3-associated phagocytosis(Liu et al., 2023). SCFAs also influence neutrophil activity, including degranulation and inflammasome activation, thereby contributing to the regulation of inflammatory responses (Liu et al., 2023). Dendritic cell migration to mesenteric lymph nodes is depicted, where antigen presentation leads to T cell differentiation (Kim et al., 2014). SCFAs influence the differentiation of T cells into Th1 and Th17 cells through cytokine signaling (Liu et al., 2023; Kim, 2021). Th17 cells produce cytokines such as IL-17A, IL-17F, and IL-22, which further activate innate lymphoid cells (ILC3), whereas Th1 cells produce interferon-gamma (IFN-γ) and activate ILC1 cells (Park et al., 2015; Ma et al., 2019). Additionally, SCFAs promote the differentiation and function of regulatory T cells (Tregs), which are critical for maintaining immune tolerance and preventing excessive inflammatory responses (Liu et al., 2023). Together, these interactions demonstrate how SCFAs act as central mediators in gut immunity, linking microbial activity in the gut with host immune regulation, and maintaining the balance between immune defense and tolerance.
Recent findings highlight the intricate interplay between SCFAs, bile acid metabolism, and the gut microbiome, revealing additional layers of immunoregulation with implications for GvHD. The gut microbiome mediates the conversion of primary bile acids produced by the liver into secondary bile acids (Houser and Tansey, 2017). SCFAs can modulate the composition and activity of bile acid-metabolizing bacteria, thereby altering the bile acid profiles within the gut, a factor that directly affects intestinal barrier integrity and immune regulation. Certain bile acids are known to reinforce the intestinal barrier, and SCFAs may modulate this relationship, potentially influencing susceptibility to GvHD (Malard et al., 2023b). Additionally, alterations in bile acid profiles driven by SCFAs can influence signaling pathways, such as the farnesoid X receptor (FXR), which plays a crucial role in inflammation and immune regulation (Riwes and Reddy, 2020; Masetti et al., 2021).
SCFA-producing bacteria in HSCT: therapeutic potential and clinical strategies
HSCT induces significant shifts in the gut microbial landscape, particularly reducing the abundance and diversity of SCFA-producing bacteria (Peled et al., 2016; Zama et al., 2017). Studies consistently report a decline in Clostridiales species, especially those belonging to the Lachnospiraceae and Ruminococcaceae families, which are major butyrate producers central to gut homeostasis (Romick-Rosendale et al., 2018; Bansal et al., 2022; Skaarud et al., 2021). These alterations are driven by a combination of factors, including dietary restrictions, antibiotic exposure, and the cytotoxic effects of chemotherapy and radiotherapy on the intestinal niche.
The restrictive, low-fiber diets commonly prescribed during the peri-transplant period markedly reduce the availability of complex carbohydrates needed to sustain SCFA-producing commensals (Riwes et al., 2023; Andermann et al., 2021; D'Amico et al., 2019). In parallel, broad-spectrum antibiotic use for prophylaxis and infection management further exerts a profound and often prolonged impact on the microbiota. These agents indiscriminately deplete obligate anaerobes essential for SCFA synthesis, leading to lasting disruptions in microbial composition (Romick-Rosendale et al., 2018; Meedt et al., 2022; Shono et al., 2016). Romick-Rosendale et al. (2018) showed that increased antibiotic exposure correlated with a significant reduction in fecal butyrate and propionate levels during the first 14 days post-HSCT. Similarly, Shono et al. (2016) reported that treatment with imipenem-cilastatin and piperacillin-tazobactam was associated with greater microbiota damage and increased GvHD-related mortality, emphasizing the unintended consequences of antimicrobial regimens.
Beyond antibiotic-driven dysbiosis, conditioning regimens, particularly intensive chemotherapy and total body irradiation, inflict additional damage on the gut microbiome. These therapies compromise mucosal integrity, diminish microbial diversity, and facilitate the expansion of pathogenic taxa (Romick-Rosendale et al., 2018; Meedt et al., 2022). Ionizing radiation has been shown to severely reduce beneficial SCFA producers such as Faecalibacterium and Bifidobacterium, and deplete Akkermansia muciniphila (A. muciniphila), a mucin-degrading bacterium crucial for maintaining epithelial homeostasis (Zhao et al., 2021; Fernandes et al., 2021).
Chemotherapy-induced microbiota alterations further exemplify the systemic consequences of gut dysbiosis in cancer therapy. In a longitudinal study of young adult cancer survivors, gut microbiota composition remained profoundly disrupted for up to six months post-chemotherapy, correlating with elevated markers of systemic inflammation and increased microbial translocation (Deleemans et al., 2019). These changes extended beyond immunological effects, contributing to neuropsychological symptoms resembling post-traumatic stress disorder (PTSD), including cognitive impairments such as memory deficits and executive dysfunction. Additionally, metabolic disturbances, including increased risk of obesity and metabolic syndrome, further underscored the long-term impact of chemotherapy on microbiome-mediated health outcomes.
In clinical and preclinical studies, abdominal irradiation led to significant losses of A. muciniphila, correlating with prolonged diarrhea in irradiated patients (He et al., 2023; Moraitis et al., 2023). Mechanistic work has demonstrated that A. muciniphila promotes gut barrier integrity through propionate-mediated activation of GPR43, which enhances expression of tight junction proteins including occludin and ZO-1 (He et al., 2023).
Microbiome disruptions in HSCT patients also profoundly affect SCFA production and metabolism, leading to cascading effects on immune function, epithelial barrier repair, and systemic inflammation. Intestinal inflammation and mucosal injury impair SCFA absorption by colonocytes, while shifts in microbial composition alter the relative ratios and types of SCFAs produced, potentially influencing their downstream immunometabolic effects (Riwes and Reddy, 2020; Romick-Rosendale et al., 2018; Sen and Thummer, 2022; Ghimire et al., 2021; Mathewson et al., 2016; Tan et al., 2014). Given that barrier dysfunction is a well-established contributor to GvHD pathogenesis, strategies aimed at restoring SCFA availability and supporting epithelial repair hold strong therapeutic potential (Riwes and Reddy, 2020; Ji et al., 2024).
By dampening inflammatory signaling and promoting tissue restitution, SCFAs emerge as key regulators of host-microbiota equilibrium with implications for GvHD modulation. Clinical studies support this role: in one cohort, reduced butyrate and propionate levels were associated with an increased incidence of chronic GvHD (Markey et al., 2020). Prolonged depletion of butyrate-producing bacteria during the early post-transplant period also correlated with greater gastrointestinal GvHD severity and increased transplant-related mortality (Meedt et al., 2022). These findings highlight the importance of preserving or restoring SCFA producers to mitigate post-transplant complications.
Emerging strategies to enhance microbiome resilience and SCFA recovery include targeted dietary interventions, probiotic administration, and microbial therapeutics. In murine models, supplementation with Bacteroides fragilis improved gut barrier integrity, increased Treg responses, and reduced GvHD severity without compromising graft-vs.-leukemia effects (Sofi et al., 2021). In clinical settings, supplementation with resistant potato starch significantly elevated fecal butyrate levels, offering a dietary route to bolster SCFA-mediated immune modulation (Riwes et al., 2023).
Preclinical studies have further demonstrated that high-fiber diets enrich SCFA producers such as Bacteroides acidifaciens, improving outcomes after radiotherapy and enhancing antitumor immunity (Then et al., 2020). Mice with elevated SCFA levels following irradiation showed improved epithelial regeneration, increased T-cell activation, and reduced treatment-related toxicity. In parallel, probiotics have shown protective effects against radiation-induced neuroinflammation and cognitive decline (Venkidesh et al., 2023). Beyond local effects, SCFAs modulate systemic immunity, enhance chemotherapy sensitivity, and regulate inflammation. Butyrate, acetate, and propionate have demonstrated synergistic anti-tumor properties, particularly in colorectal cancer, by promoting cytotoxic T-cell function and modulating epigenetic pathways (Al-Qadami et al., 2022).
Altogether, these findings underscore the therapeutic promise of restoring SCFA-producing communities in HSCT recipients. Understanding and leveraging these microbiota-derived metabolites may represent a pivotal step in designing microbiome-based strategies to enhance immune recovery, reduce transplant-related morbidity, and improve long-term outcomes. The main findings of studies investigating SCFA roles post-HSCT are summarized in Tables 1, 2.
Table 1. Summary of key findings from observational studies investigating the role of SCFAs in post-HSCT patients.
Table 2. Summary of key findings from Interventional studies investigating the role of SCFAs in post-HSCT patients.
Microbial metabolites and engineered therapies in HSCT: discussion and future perspectives
Short-chain fatty acids (SCFAs), particularly butyrate, have emerged as critical mediators of intestinal and systemic immune homeostasis, with profound implications for hematopoietic stem cell transplantation (HSCT) outcomes (Romick-Rosendale et al., 2018; Riwes et al., 2023; D'Amico et al., 2019; Meedt et al., 2022). Acting at the intersection of microbiome-host crosstalk, butyrate modulates inflammatory pathways, epithelial repair, and epigenetic programming. Its multifaceted roles in shaping immune reconstitution and barrier function render it a promising candidate for therapeutic exploitation. However, translating these microbiota-derived metabolites into clinical interventions demands a transition from descriptive associations toward a mechanistic, causality-based framework.
Despite compelling evidence for SCFA-mediated immune modulation, the precise mechanistic pathways remain incompletely understood (Zhao et al., 2025). Current studies inconsistently implicate GPR43, GPR41, or GPR109A as dominant receptors; the relative contribution of each remains unclear due to divergent findings in knockout models and overlapping ligand specificity (Muralitharan et al., 2023; Behler-Janbeck et al., 2024). Moreover, context-specific responses, shaped by the tissue microenvironment, immune status, and epithelial-immune crosstalk, are not consistently delineated, making it difficult to predict therapeutic efficacy across varied clinical settings (Zhao et al., 2025; Dai et al., 2025). Most models further isolate SCFAs from the broader “metabolomic milieu”, neglecting complex interactions with microbial metabolites such as bile acids or tryptophan derivatives (Chulenbayeva et al., 2025). This reductionist approach may mask synergistic or antagonistic effects, thereby limiting clinical translatability (Chulenbayeva et al., 2025).
The therapeutic potential of SCFAs is rooted in their ability to exert potent anti-inflammatory effects by inducing regulatory T cells (Tregs) and inhibiting histone deacetylases (HDACs), thus orchestrating gene expression across immune and epithelial compartments (Boets et al., 2017; Fujiwara et al., 2018; Kespohl et al., 2017). Beyond the gut, recent findings reveal that SCFAs influence hematopoietic recovery by regulating the epigenetic landscapes of progenitors, impacting cell fate through chromatin remodeling and metabolic rewiring (Ji et al., 2024; Peled et al., 2016; Park et al., 2015; Chi et al., 2023; Nshanian et al., 2025; Kopczyńska and Kowalczyk, 2024). Notably, butyrate enhances chromatin accessibility via histone acetylation to promote epithelial lineage specification, a paradigm directly relevant to mitigating epithelial injury post-conditioning (Stein and Riber, 2023).
However, the role of butyrate in HSCT may be biphasic and context-dependent, acting as a “double-edged sword” depending on the structural integrity of the intestinal crypts. While butyrate is protective during steady-state or preventive phases, it may be detrimental during active mucosal injury. Mechanistically, Kaiko et al. (2016) demonstrated that while differentiated colonocytes utilize butyrate as a primary energy source, colonic stem/progenitor cells are susceptible to its growth-inhibitory effects via a Foxo3-dependent pathway. In the healthy gut, the crypt architecture acts as a “metabolic barrier,” where differentiated colonocytes at the crypt surface metabolize luminal butyrate, preventing it from reaching the stem cell niche at the base (Kaiko et al., 2016). In the context of HSCT, the profound mucosal denudation caused by conditioning or acute GvHD likely breaches this shield, exposing stem cells to inhibitory butyrate concentrations and thereby delaying epithelial repair. This mechanistic rationale is reinforced by clinical observations from Golob et al. (2019) which linked a higher abundance of butyrogenic bacteria following the onset of acute gastrointestinal GvHD with the development of steroid-refractory and chronic GvHD. These findings suggest that the therapeutic window for SCFA interventions must be carefully calibrated; butyrate-producing consortia may reinforce the barrier early in the transplant course but could potentially hinder recovery if present during windows of severe epithelial denudation.
To address these complexities and the limitations of traditional probiotics, which suffer from poor engraftment or safety concerns in immunocompromised hosts (Yazdandoust et al., 2023; Ma et al., 2023; Lee et al., 2023), the field is shifting toward “living therapeutics” and precision delivery. Synthetic biology has introduced a new frontier: programmed Saccharomyces cerevisiae (Wu et al., 2023) and E. coli (Jin et al., 2025) chassis designed to detect inflammatory cues and release butyrate or postbiotics in a controlled, spatiotemporal manner. Such engineered systems could potentially personalize metabolite release to avoid “toxic” windows while maximizing local mucosal repair. Parallel to these efforts, the development of butyrate-loaded nanocarriers and pH-sensitive capsules is essential to ensure targeted colonic delivery, overcoming bioavailability issues of dietary fiber (Lopes et al., 2023).
Crucially, the immunomodulatory role of the microbiome extends beyond a single metabolite class. Tryptophan catabolites activate the aryl hydrocarbon receptor (AhR) to promote mucosal tolerance, while secondary bile acids influence T cell polarization (Michonneau et al., 2019; Landfried et al., 2011; Swimm et al., 2018; Tyszka et al., 2024; Haring et al., 2021). Emerging data suggest a “metabolic complementarity,” where SCFAs may synergize with tryptophan and bile acid pathways to reinforce the immunological barrier post-HSCT (Cao et al., 2024). Failure to account for these interactions, alongside cross-species discrepancies between murine and human models, remains a significant hurdle in developing regulatory-grade therapeutics.
Future research must prioritize causal inference through harmonized, precision-driven trial designs. Patient stratification should move beyond clinical GvHD grading to include validated biomarkers of epithelial injury and longitudinal metabolomic profiling to identify the optimal “metabolic window” for intervention. Trials must standardize delivery routes, dosing, and colonic release profiles while rigorously adjusting for confounders such as corticosteroids and antimicrobials. Ultimately, the microbiome is a dynamic metabolic organ. Realizing its promise will require a convergence of precision nutrition, synthetic biology, and patient-specific profiling to unlock a new era of transplant medicine, one where engineered microbial bioactivity is precisely timed to support immune reconstitution and survival.
Author contributions
CH: Methodology, Conceptualization, Writing – original draft, Investigation, Visualization, Data curation, Funding acquisition, Project administration, Writing – review & editing. EK: Writing – review & editing, Validation, Conceptualization. M-JB: Writing – review & editing, Conceptualization, Validation. GK: Writing – review & editing. MM: Writing – review & editing. DK: Methodology, Conceptualization, Investigation, Writing – review & editing, Funding acquisition, Project administration. PL: Validation, Writing – review & editing. WL: Writing – review & editing, Validation. AB: Supervision, Writing – review & editing, Project administration, Funding acquisition, Conceptualization, Validation. MA: Project administration, Validation, Conceptualization, Writing – review & editing, Supervision, Funding acquisition.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Council for Scientific Research in Lebanon (CNRS-L) through a doctoral scholarship and by Saint Joseph University of Beirut (USJ) via a research grant. Additional support was provided by the L'Oréal-UNESCO For Women in Science Fellowship (Levant Young Talents), the “Talents de Demain” grant from the Embassy of France in Lebanon, and a research fellowship from the French Ministry of Europe and Foreign Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Acknowledgments
CH warmly acknowledges the late Professor Dolla Karam Sarkis for her generous support, insightful guidance, and enduring encouragement, which left a lasting impact on this work. She also thanks the research councils and internal funding programmes of Saint Joseph University of Beirut (USJ), together with its ethics committee, as well as the American University of Beirut (AUB), including its Institutional Review Board and Office of Grants and Contracts, for their support throughout the project.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
3-HAA, 3-Hydroxyanthranilic Acid ; 3-HK, 3-Hydroxykynurenine; 3-ICA, Indole 3-Carboxaldehyde; 5-HIAA, 5-Hydroxyindoleacetic acid; aGvHD, Acute GvHD; AhR, Aryl Hydrocarbon ; A. muciniphila, Akkermansia muciniphila; cGvHD, Chronic GvHD; CTLA4, Cytotoxic T-Lymphocyte Associated Protein 4; EN, Enteral Nutrition; ESBL, Extended-Spectrum β-Lactamase; FFAR, Free Fatty Acid Receptors; FMT, Fecal Microbiota Transplantation; FOS, Fructooligosaccharide; FOXP3, Forkhead Box P3; FXR, Farnesoid X Receptor; GM, Gut Microbiota; GPR, G Protein-Coupled Receptors; GvHD, Graft-Versus-Host Disease; GVL, Graft-Versus-Leukemia; hAMSCs, Human Amniotic Mesenchymal Stem Cells; HDAC, Histone Deacetylase; HLA, Human Leukocyte Antigen; HSCT, Hematopoietic Stem Cell Transplantation; IDO, Indoleamine 2,3-Dioxygenase; IECs, Intestinal Epithelial Cells; IFN-γ, Interferon-Gamma; IgA, Immunoglobulin A; IL, Interleukin; ILC, Innate Lymphoid Cells; IMM, Immunomodulatory Metabolites; IMM-RI, Immunomodulatory Metabolites Risk Index; JAM-C, Junctional adhesion molecules-C; KYNA, Kynurenic Acid; LC3, Type 3 Innate Lymphoid Cells; MAPK, Mitogen-Activated Protein Kinase; MCT-1, Monocarboxylate Transporter 1; mDCs, Monocyte-Derived Dendritic Cells; NF-κB, Nuclear Factor-kappa B; NLRP3, NOD-Like Receptor Protein 3; NRM, Non-Relapse Mortality; PA, Picolinic Acid; PN, Parenteral Nutrition; QA, Quinolinic Acid; RPS, Resistant Potato Starch; SCFAs, Short-Chain Fatty Acids; SMCT-1, Sodium-Coupled Monocarboxylate Transporter 1; TBI, Total Body Irradiation; Th1, T Helper 1; Th17, T Helper 17; TNF-α, Tumor Necrosis Factor-Alpha; Tregs, Regulatory T Cells; UDCA, Ursodeoxycholic Acid; ZO-1, Zonula occludens-1.
References
Abdelhalim, K. A. (2024). Short-chain fatty acids (SCFAs) from gastrointestinal disorders, metabolism, epigenetics, central nervous system to cancer - A mini-review. Chem Biol Interact. 388:110851. doi: 10.1016/j.cbi.2023.110851
Adams, L. (2024). A Holistic Study of the Effect of the Murine Microbiome on Metabolism and Systemic Inflammation Using Integrated Molecular Imaging Technologies [PhD thesis]. University of Glasgow. Available online at: https://theses.gla.ac.uk/84322/
Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., and Bowen, J. M. (2022). Gut microbiota-derived short-chain fatty acids: impact on cancer treatment response and toxicities. Microorganisms 10:2048. doi: 10.3390/microorganisms10102048
Andermann, T. M., Fouladi, F., Tamburini, F. B., Sahaf, B., Tkachenko, E., Greene, C., et al. (2021). A fructo-oligosaccharide prebiotic is well tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial. Transplant Cell Ther. 27, 932.e1–932.e11. doi: 10.1016/j.jtct.2021.07.009
Artacho, A., González-Torres, C., Gómez-Cebrián, N., Moles-Poveda, P., Pons, J., Jiménez, N., et al. (2024). Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases. Microbiome 12, 1–26. doi: 10.1186/s40168-024-01948-0
Azhar Ud Din, M., Lin, Y., Lyu, C., Yi, C., Fang, A., Mao, F., et al. (2025). Advancing therapeutic strategies for graft-vs.-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions. Mol. Med. 31:2. doi: 10.1186/s10020-024-01060-x
Bansal, R., Park, H., Taborda, C. C., Gordillo, C., Mapara, M. Y., Assal, A., et al. (2022). Antibiotic exposure, not alloreactivity, is the major driver of microbiome changes in hematopoietic cell transplantation. Transplant. Cell Ther. 28, 135–144. doi: 10.1016/j.jtct.2021.12.015
Behler-Janbeck, F., Baranowsky, A., Yorgan, T. A., Attané, C., Ivaska, K. K., Loisay, L., et al. (2024). The short-chain fatty acid receptors Gpr41/43 regulate bone mass by promoting adipogenic differentiation of mesenchymal stem cells. Front. Endocrinol. 15. doi: 10.3389/fendo.2024.1392418
Boets, E., Gomand, S. V., Deroover, L., Preston, T., Vermeulen, K., De Preter, V., et al. (2017). Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. J. Physiol. 595, 541–555. doi: 10.1113/JP272613
Bu, X., Gao, Y., Pan, W., Liu, L., Wang, J., Yin, Z., et al. (2024). Human Amniotic Membrane-Derived Mesenchymal Stem Cells Prevent Acute Graft-Vs.-Host Disease in an Intestinal Microbiome-Dependent Manner. Transplant Cell Ther. 30, 189.e1–189.e13. doi: 10.1016/j.jtct.2023.11.005
Bu, X., Pan, W., Wang, J., Liu L, Yin Z, Jin H, et al. (2023). Therapeutic effects of HLA-G5 overexpressing hAMSCs on aGVHD After Allo-HSCT: involving in the gut microbiota at the intestinal barrier. J. Inflamm. Res. 16, 3669–3685. doi: 10.2147/JIR.S420747
Burgos da Silva, M., Ponce, D. M., Dai, A. M., Devlin, S., Gomes, A. L. C., Moore, G., et al. (2022). Preservation of the fecal microbiome is associated with reduced severity of graft-vs.-host disease. Blood. 140, 2385–2397. doi: 10.1182/blood.2021015352
Busnelli, M., Manzini, S., and Chiesa, G. (2019). The Gut microbiota affects host pathophysiology as an endocrine organ: a focus on cardiovascular disease. Nutrients 12:79. doi: 10.3390/nu12010079
Cao, S., Budina, E., Raczy, M. M., Solanki, A., Nguyen, M., Beckman, T. N., et al. (2024). A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice. Nat Biomed Eng. 8, 611–627. doi: 10.1038/s41551-024-01190-x
Chang, P. V., Hao, L., Offermanns, S., and Medzhitov, R. (2014). The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. 111, 2247–2252. doi: 10.1073/pnas.1322269111
Chen, J., and Vitetta, L. (2020). The role of butyrate in attenuating pathobiont-induced hyperinflammation. Immune Netw. 20:e15. doi: 10.4110/in.2020.20.e15
Chi, M., Jiang, T., He, X., Peng, H., Li, Y., Wang, L., et al. (2023). Role of gut microbiota and oxidative stress in the progression of transplant-related complications following hematopoietic stem cell transplantation. Oxid. Med. Cell Longev. 2023:3532756. doi: 10.1155/2023/3532756
Chulenbayeva, L., Issilbayeva, A., Sailybayeva, A., Bekbossynova, M., Kozhakhmetov, S., Kushugulova, A., et al. (2025). Short-chain fatty acids and their metabolic interactions in heart failure. Biomedicines 13:343. doi: 10.3390/biomedicines13020343
Chun, E., Lavoie, S., Fonseca-Pereira, D., Bae, S., Michaud, M., Hoveyda, H. R., et al. (2019). Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity. Immunity 51, 871–884.e6. doi: 10.1016/j.immuni.2019.09.014
Corcione, S., Ferrocino, I., Lupia, T., Busca, A., Bianco, G., Dellacasa, C., et al. (2025). Influence of ESBL colonization status on gut microbiota composition during allogenic hematopoietic stem cell transplantation. Sci Rep. 15:275. doi: 10.1038/s41598-025-85128-6
Corrêa-Oliveira, R., Fachi, J. L., Vieira, A., Sato, F. T., and Vinolo, M. A. R. (2016). Regulation of immune cell function by short-chain fatty acids. Clin. Transl. Immunol. 5:e73 . doi: 10.1038/cti.2016.17
Dai, W., Chen, X., Zhou, H., Liu, N., Jin, M., Guo, Z., et al. (2025). Microbiota modulation for infectious complications following allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies. Front. Pediatr. 13:1509612. doi: 10.3389/fped.2025.1509612
Dalile, B., Van Oudenhove, L., Vervliet, B., and Verbeke, K. (2019). The role of short-chain fatty acids in microbiota–gut–brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478. doi: 10.1038/s41575-019-0157-3
D'Amico, F., Biagi, E., Rampelli, S., Fiori, J., Zama, D., Soverini, M., et al. (2019). Enteral nutrition in pediatric patients undergoing hematopoietic sct promotes the recovery of gut microbiome homeostasis. Nutrients 11:2958. doi: 10.3390/nu11122958
DeFilipp, Z., Damania, A. V., Kim, H. T., Chang, C. C., El-Jawahri, A., McAfee, S. L., et al. (2024). Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract. Blood Adv. 8, 2074–2084. doi: 10.1182/bloodadvances.2024012556
Deleemans, J. M., Chleilat, F., Reimer, R. A., Henning, J. W., Baydoun, M., Piedalue, K. A., et al. (2019). The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol. BMC Cancer 19:1243. doi: 10.1186/s12885-019-6473-8
Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L. R., and Scaldaferri, F. (2024). Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg. Med. 19, 275–293. doi: 10.1007/s11739-023-03374-w
Dulery, E. (2023). Understanding graft-vs.-host disease: a complex complication of transplantation. Acute Chron. Dis. Rep. 7, 1–2. doi: 10.35248/ACDR.23.07.191
Faraci, M., Bonaretti, C., Dell'Orso, G., Pierri, F., Giardino, S., Angiero, F., et al. (2024). Association between oral and fecal microbiome dysbiosis and treatment complications in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. Sci. Rep. 14:6708. doi: 10.1038/s41598-024-55690-6
Fernandes, A., Oliveira, A., Soares, R., and Barata, P. (2021). The effects of ionizing radiation on gut microbiota, a systematic review. Nutrients 13:3025. doi: 10.3390/nu13093025
Ferrara, J. L., Levine, J. E., Reddy, P., and Holler, E. (2009). Graft-vs.-host disease. The Lancet 373, 1550–1561. doi: 10.1016/S0140-6736(09)60237-3
Flowers, M. E. D., and Martin, P. J. (2015). How we treat chronic graft-vs.-host disease. Blood 125, 606–615. doi: 10.1182/blood-2014-08-551994
Fock, E., and Parnova, R. (2023). Mechanisms of blood–brain barrier protection by microbiota-derived short-chain fatty acids. Cells 12:657. doi: 10.3390/cells12040657
Frampton, J., Murphy, K. G., Frost, G., and Chambers, E. S. (2020). Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function. Nat. Metab. 2, 840–848. doi: 10.1038/s42255-020-0188-7
Fujiwara, H., Docampo, M. D., Riwes, M., Peltier, D., Toubai, T., Henig, I., et al. (2018). Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat Commun. 9:3674. doi: 10.1038/s41467-018-06048-w
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450. doi: 10.1038/nature12721
Fusco, W., Lorenzo, M. B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., et al. (2023). Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 15:2211. doi: 10.3390/nu15092211
Gavriilaki, E., Christoforidi, M., Ouranos, K., Minti, F., Mallouri, D., Varelas, C., et al. (2024). Alteration of gut microbiota composition and diversity in acute and/or chronic graft-vs.-host disease following hematopoietic stem cell transplantation: a prospective cohort study. Int. J. Mol. Sci. 25:5789. doi: 10.3390/ijms25115789
Ghimire, S., Weber, D., Hippe, K., Meedt, E., Hoepting, M., Kattner, A. S., et al. (2021). GPR expression in intestinal biopsies from sct patients is upregulated in gvhd and is suppressed by broad-spectrum antibiotics. Front. Immunol. 12:753287. doi: 10.3389/fimmu.2021.753287
Ghosh, S. S., Wang, J., Yannie, P. J., and Ghosh, S. (2020). Intestinal barrier dysfunction, lps translocation, and disease development. J. Endocr. Soc. 4:bvz039. doi: 10.1210/jendso/bvz039
Golob, J. L., DeMeules, M. M., Loeffelholz, T., Quinn, Z. Z., Dame, M. K., Silvestri, S. S., et al. (2019). Butyrogenic bacteria after acute graft-vs.-host disease (GVHD) are associated with the development of steroid-refractory GVHD. Blood Adv. 3, 2866–2869. doi: 10.1182/bloodadvances.2019000362
Gu, B. H., Kim, M., and Yun, C. H. (2021). Regulation of Gastrointestinal Immunity by Metabolites. Nutrients 13:167. doi: 10.3390/nu13010167
Haak, B. W., Littmann, E. R., Chaubard, J. L., Pickard, A. J., Fontana, E., Adhi, F., et al. (2018). Impact of gut colonization with butyrate producing microbiota on respiratory viral infection following allo-HCT. Blood 131, 2978–2986. doi: 10.1182/blood-2018-01-828996
Habibi, S., and Rashidi, A. (2023). Fecal microbiota transplantation in hematopoietic cell transplant and cellular therapy recipients: lessons learned and the path forward. Gut Microbes 15:2229567. doi: 10.1080/19490976.2023.2229567
Hamilton, B. K. (2021). Updates in chronic graft-vs.-host disease. Hematology 2021, 648–654. doi: 10.1182/hematology.2021000301
Hammerhøj, A., Gubatan, J. M., and Nielsen, O. H. (2024). Gut microbiome and disorders of the gastrointestinal tract. Microorganisms 12:576. doi: 10.3390/microorganisms12030576
Han, L., Sun, X., Kong, J., Li, J., Feng, K., Bai, Y., et al. (2024). Multi-omics analysis reveals a feedback loop amplifying immune responses in acute graft-vs.-host disease due to imbalanced gut microbiota and bile acid metabolism. J Transl Med. 22, 1–24. doi: 10.1186/s12967-024-05577-x
Haring, E., Uhl, F. M., Andrieux, G., Proietti, M., Bulashevska, A., Sauer, B., et al. (2021). Bile acids regulate intestinal antigen presentation and reduce graft-vs.-host disease without impairing the graft-vs.-leukemia effect. Haematologica 106:2131. doi: 10.3324/haematol.2019.242990
He, K. Y., Lei, X. Y., Wu, D. H., Zhang, L., Li, J. Q., Li, Q. T., et al. (2023). Akkermansia muciniphila protects the intestine from irradiation-induced injury by secretion of propionic acid. Gut Microbes. 15:2293312. doi: 10.1080/19490976.2023.2293312
Heidegger, S., van den Brink, M. R. M., Haas, T., and Poeck, H. (2014). The role of pattern-recognition receptors in graft-vs.-host disease and graft-vs.-leukemia after allogeneic stem cell transplantation. Front. Immunol. 5:96047. doi: 10.3389/fimmu.2014.00337
Houser, M. C., and Tansey, M. G. (2017). The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? NPJ Parkinsons Dis. 3:3. doi: 10.1038/s41531-016-0002-0
Isobe, J., Maeda, S., Obata, Y., Iizuka, K., Nakamura, Y., Fujimura, Y., et al. (2020). Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon. Int Immunol. 32, 243–258. doi: 10.1093/intimm/dxz078
Jagasia, M. H., Greinix, H. T., Arora, M., et al. (2015). National institutes of health consensus development project on criteria for clinical trials in chronic graft-vs.-host disease: i. the 2014 diagnosis and staging working group report. Biol. Blood Marrow Transplant. 21, 389–401.e1. doi: 10.1016/j.bbmt.2014.12.035
Jansen, S. A., Nieuwenhuis, E. E. S., Hanash, A. M., and Lindemans, C. A. (2022). Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-vs.-host disease. Mucosal. Immunol. 15, 605–619. doi: 10.1038/s41385-022-00527-6
Ji, H., Feng, S., Liu, Y., Cao, Y., Lou, H., Effect, L. i. Z., et al. (2024). of GVHD on the gut and intestinal microflora. Transpl. Immunol. 82:101977. doi: 10.1016/j.trim.2023.101977
Jin, K., Huang, Y., Che, H., and Wu, Y. (2025) . Engineered bacteria for disease diagnosis treatment using synthetic biology. Microb Biotechnol. 18:e70080. doi: 10.1111/1751-7915.70080
Jin, S., Zhang, Y., Zhou, F., Chen, X., Sheng, J., Zhang, J. T. I. G. I. T., et al. (2022). A promising target to overcome the barrier of immunotherapy in hematological malignancies. Front. Oncol. 12:1091782. doi: 10.3389/fonc.2022.1091782
Kaiko, G. E., Ryu, S. H., Koues, O. I., Collins, P. L., Solnica-Krezel, L., Pearce, E. J., et al. (2016). Erratum: the colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 167:1137. doi: 10.1016/j.cell.2016.05.018
Karim, Md., Iqbal, S., Mohammad, S., Morshed, M. N., Haque, M. A., Mathiyalagan, R., et al. (2024). Butyrate's (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer. Arch. Microbiol. 206:137. doi: 10.1007/s00203-024-03834-7
Kespohl, M., Vachharajani, N., Luu, M., Harb, H, Pautz, S., Wolff, S., et al. (2017). The microbial metabolite butyrate induces expression of Th1- associated factors in cD4+ T cells. Front. Immunol. 8 doi: 10.3389/fimmu.2017.01036
Khalil, Z., and Maher, S. (2024). The impact of microbiome dysbiosis on hematopoietic stem cell transplantation outcomes: a review article. Cureus. 16:e63995. doi: 10.7759/cureus.63995
Kim, C. H. (2021). Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell. Mol. Immunol. 18, 1161–1171. doi: 10.1038/s41423-020-00625-0
Kim, C. H., Park, J., and Kim, M. (2014). Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw. 14:277. doi: 10.4110/in.2014.14.6.277
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., and Bäckhed, F. (2016). from dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 165, 1332–1345. doi: 10.1016/j.cell.2016.05.041
Kondo, T., Chiba, T., and Tousen, Y. (2022). Short-chain fatty acids, acetate and propionate, directly upregulate osteoblastic differentiation. Int. J. Food Sci. Nutr. 73, 800–808. doi: 10.1080/09637486.2022.2078285
Kopczyńska, J., and Kowalczyk, M. (2024). The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity. Front Immunol. 15:1380476. doi: 10.3389/fimmu.2024.1380476
Landfried, K., Zhu, W., Waldhier, M. C., Schulz, U., Ammer, J., Holler, B., et al. (2011). Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood. 118, 6971–6974. doi: 10.1182/blood-2011-06-357814
Lee, Z. Y., Lew, C. C. H., Ortiz-Reyes, A., Patel, J. J., Wong, Y. J., Loh, C. T. I., et al. (2023). Benefits and harm of probiotics and synbiotics in adult critically ill patients. A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Clin. Nutr. 42, 519–531. doi: 10.1016/j.clnu.2023.01.019
Li, J., Zhang, X., Chen, Y., Zheng, Q., Zhao, M., Jiang, H. A., et al. (2022). Promising insight: the potential influence and therapeutic value of the gut microbiota in GI GVHD. Oxid Med Cell Longev. 2022:2124627. doi: 10.1155/2022/2124627
Li, Y., Huang, Y., Liang, H., Wang, W., Li, B., Liu, T., et al. (2023). The roles and applications of short-chain fatty acids derived from microbial fermentation of dietary fibers in human cancer. Front. Nutr. 10:1243390. doi: 10.3389/fnut.2023.1243390
Lin, D., Hu, B., Li, P., Zhao, Y., Xu, Y., Wu, D., et al. (2021). Roles of the intestinal microbiota and microbial metabolites in acute GVHD. Exp. Hematol. Oncol. 10, 1–19. doi: 10.1186/s40164-021-00240-3
Liu, X. F., Shao, J. H., Liao, Y. T., Wang, L. N., Jia, Y., Dong, P. J., et al. (2023). Regulation of short-chain fatty acids in the immune system. Front. Immunol. 14. doi: 10.3389/fimmu.2023.1186892
Lopes, S. A., Roque-Borda, C. A., Duarte, J. L., Di Filippo, L. D., Borges Cardoso, V. M., Pavan, F. R., et al. (2023). Delivery strategies of probiotics from nano- and microparticles: trends in the treatment of inflammatory bowel disease—an overview. Pharmaceutics 15:2600. doi: 10.3390/pharmaceutics15112600
Luu, M., Monning, H., and Visekruna, A. (2020). Exploring the molecular mechanisms underlying the protective effects of microbial scfas on intestinal tolerance and food allergy. Front. Immunol. 11:1225. doi: 10.3389/fimmu.2020.01225
Luu, M., Weigand, K., Wedi, F., Breidenbend, C., Leister, H., Pautz, S., et al. (2018). Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate. Sci. Rep. 8:14430. doi: 10.1038/s41598-018-32860-x
Ma, H., Tao, W., and Zhu, S. T. (2019). lymphocytes in the intestinal mucosa: defense and tolerance. Cell Mol Immunol. 16, 216–224. doi: 10.1038/s41423-019-0208-2
Ma, T., Shen, X., Shi, X., Sakandar, H. A., Quan, K., Li, Y., et al. (2023). Targeting gut microbiota and metabolism as the major probiotic mechanism - An evidence-based review. Trends Food Sci. Technol. 138, 178–198. doi: 10.1016/j.tifs.2023.06.013
Malard, F., Gasc, C., Plantamura, E., and Doré, J. (2018). High gastrointestinal microbial diversity and clinical outcome in graft-vs.-host disease patients. Bone Marrow Transplant. 53, 1493–1497. doi: 10.1038/s41409-018-0254-x
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., and Mohty, M. (2023a). Acute graft-vs.-host disease. Nat. Rev. Dis. Prim. 9, 1–18. doi: 10.1038/s41572-023-00438-1
Malard, F., Loschi, M., Huynh, A., Cluzeau, T., Guenounou, S., Legrand, F., et al. (2023b). Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-vs.-host disease: a single-arm, multicentre phase 2 trial. EClinicalMedicine 62:102111. doi: 10.1016/j.eclinm.2023.102111
Mann, E. R., Lam, Y. K., and Uhlig, H. H. (2024). Short-chain fatty acids: linking diet, the microbiome and immunity. Nat. Rev. Immunol. 24, 577–595. doi: 10.1038/s41577-024-01014-8
Markey, K. A., Schluter, J., Gomes, A. L. C., Littmann, E. R., Pickard, A. J., Taylor, B. P., et al. (2020). The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood 136, 130–136. doi: 10.1182/blood.2019003369
Masetti, R., Leardini, D., Muratore, E., Fabbrini, M., D'Amico, F., Zama, D., et al. (2023). Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children. Blood 142, 1387–1398. doi: 10.1182/blood.2023020026
Masetti, R., Zama, D., Leardini, D., Muratore, E., Turroni, S., Brigidi, P., et al. (2021). Microbiome-derived metabolites in allogeneic hematopoietic stem cell transplantation. Int. J. Mol. Sci. 22:1197. doi: 10.3390/ijms22031197
Mathewson, N. D., Jenq, R., Mathew, A. V., Koenigsknecht, M., Hanash, A., Toubai, T., et al. (2016). Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-vs.-host disease. Nat Immunol. 17, 505–513. doi: 10.1038/ni.3400
Meedt, E., Hiergeist, A., Gessner, A., Dettmer, K., Liebisch, G., Ghimire, S., et al. (2022). Prolonged suppression of butyrate-producing bacteria is associated with acute gastrointestinal graft-vs-host disease and transplantation-related mortality after allogeneic stem cell transplantation. Clin. Infect. Dis. 74, 614–621. doi: 10.1093/cid/ciab500
Michonneau, D., Latis, E., Curis, E., Dubouchet, L., Ramamoorthy, S., Ingram, B., et al. (2019). Metabolomics analysis of human acute graft-vs.-host disease reveals changes in host and microbiota-derived metabolites. Nat. Commun. 10, 1–15. doi: 10.1038/s41467-019-13498-3
Minagar, A., and Jabbour, R. (2025). Correction to: the human gut microbiota: a dynamic biologic factory. Adv Biochem Eng Biotechnol. 189, 243–243. doi: 10.1007/10_2024_253
Miura, Y., Thoburn, C. J., Bright, E. C., Chen, W., Nakao, S., Hess, A. D., et al. (2002). Cytokine and chemokine profiles in autologous graft-vs.-host disease (GVHD): Interleukin 10 and interferon γ may be critical mediators for the development of autologous GVHD. Blood 100, 2650–2658. doi: 10.1182/blood-2002-01-0176
Montassier, E., Gastinne, T., Vangay, P., Al-Ghalith, GA, Bruley des Varannes, S, Massart, S., et al. (2015). Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol. Ther. 42, 515–528. doi: 10.1111/apt.13302
Moraitis, I., Guiu, J., and Rubert, J. (2023). Gut microbiota controlling radiation-induced enteritis and intestinal regeneration. Trends Endocrinol. Metabol. 34, 489–501. doi: 10.1016/j.tem.2023.05.006
Muralitharan, R. R., Zheng, T., Dinakis, E., Xie, L., Babaro-Wahl, A., Jama, H. A., et al. (2023). GPR41/43 regulates blood pressure by improving gut epithelial barrier integrity to prevent TLR4 activation and renal inflammation. bioRxiv. 533376. doi: 10.1101/2023.03.20.533376
Nshanian, M., Gruber, J. J., Geller, B. S., Chleilat, F., Lancaster, S. M., White, S. M., et al. (2025). Short-chain fatty acid metabolites propionate and butyrate are unique epigenetic regulatory elements linking diet, metabolism and gene expression. Nat. Metab. 7, 196–211. doi: 10.1038/s42255-024-01191-9
Park, J., Kim, M., Kang, S. G., Jannasch, A. H., Cooper, B., Patterson, J., et al. (2015). Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway. Mucosal. Immunol. 8, 80–93. doi: 10.1038/mi.2014.44
Peled, J. U., Gomes, A. L., Stein-Thoeringer, C. K., Slingerland, J. B., and Slingerland, A. E„ (2018). Multicenter microbiota analysis indicates that Pre-hct microbiota injury is prevalent across geography predicts poor overall survival. Blood 132, 811–811. doi: 10.1182/blood-2018-99-116967.
Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., et al. (2020). Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822–834. doi: 10.1056/NEJMoa1900623
Peled, J. U., Jenq, R. R., Holler, E., and van den Brink, M. R. M. (2016). Role of gut flora after bone marrow transplantation. Nat. Microbiol. 1:16036. doi: 10.1038/nmicrobiol.2016.36
Pianko, M. J., and Golob, J. L. (2022). Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation. Cancer Metastasis Rev. 41, 367–382. doi: 10.1007/s10555-022-10033-7
Pitea, M., Canale, F. A., Porto, G., Verduci, C., Utano, G., Policastro, G., et al. (2023). The role of MicroRNA in graft-vs.-host-disease: a review. Genes 14:1796. doi: 10.3390/genes14091796
Rekha, K., Venkidasamy, B., Samynathan, R., Nagella, P., Rebezov, M., Khayrullin, M., et al. (2024). Short-chain fatty acid: an updated review on signaling, metabolism, and therapeutic effects. Crit. Rev. Food Sci. Nutr. 64, 2461–2489. doi: 10.1080/10408398.2022.2124231
Ríos-Covián, D., Ruas-Madiedo, P., Margolles, A., Gueimonde, M., de los Reyes-Gavilán, CG, and Salazar, N. (2016). Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 7:185. doi: 10.3389/fmicb.2016.00185
Riwes, M., and Reddy, P. (2020). Short chain fatty acids: postbiotics/metabolites and graft vs. host disease colitis. Semin Hematol. 57, 1–6. doi: 10.1053/j.seminhematol.2020.06.001
Riwes, M. M., Golob, J. L., Magenau, J., Shan, M., Dick, G., Braun, T., et al. (2023). Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat. Med. 29, 2805–2813. doi: 10.1038/s41591-023-02587-y
Romick-Rosendale, L. E., Haslam, D. B., Lane, A., Denson, L., Lake, K., Wilkey, A., et al. (2018). Antibiotic exposure and reduced short chain fatty acid production after hematopoietic stem cell transplant. Biol. Blood Marrow Transplant. 24, 2418–2424. doi: 10.1016/j.bbmt.2018.07.030
Rückert, T., Andrieux, G., Boerries, M., Hanke-Müller, K., Woessner, N. M., Doetsch, S., et al. (2022). Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 14:eabp9675 doi: 10.1126/scitranslmed.abp9675
Saleri, R., Borghetti, P., Ravanetti, F., Cavalli, V., Ferrari, L., De Angelis, E., et al. (2022). Effects of different short-chain fatty acids (SCFA) on gene expression of proteins involved in barrier function in IPEC-J2. Porcine Health Manag. 8:21. doi: 10.1186/s40813-022-00264-z
Schulthess, J., Pandey, S., Capitani, M., Rue-Albrecht, K. C., Arnold, I., Franchini, F., et al. (2019). The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 50, 432–445.e7. doi: 10.1016/j.immuni.2018.12.018
Schwabkey, Z. I., Wiesnoski, D. H., Chang, C. C., Tsai, WB, Pham, D, Ahmed, SS, et al. (2022). Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci. Transl. Med. 14:eabo3445. doi: 10.1126/scitranslmed.abo3445
Sen, T., and Thummer, R. P. (2022). The impact of human microbiotas in hematopoietic stem cell and organ transplantation. Front Immunol. 13:932228. doi: 10.3389/fimmu.2022.932228
Shono, Y., Docampo, M. D., Peled, J. U., Perobelli, S. M., Velardi, E., Tsai, J. J., et al. (2016). Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 8:339ra71. doi: 10.1126/scitranslmed.aaf2311
Skaarud, K. J., Hov, J. R., Hansen, S. H., Kummen, M., Valeur, J., Seljeflot, I., et al. (2021). Mortality and microbial diversity after allogeneic hematopoietic stem cell transplantation: secondary analysis of a randomized nutritional intervention trial. Sci. Rep. 11:11593. doi: 10.1038/s41598-021-90976-z
Sofi, M. H., Wu, Y., Ticer, T., Schutt, S., Bastian, D., Choi, H. J., et al. (2021). A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD. JCI Insight 6:e136841. doi: 10.1172/jci.insight.136841
Sohouli, M. H., Zahmatkesh, A., Khan, Z., Behfar, M., Hamidieh, A. A., Rohani, P., et al. (2025). Gut microbiota variation and diversity and gut graft-vs.-host disease (GVHD) in pediatrics: A systematic review. Transpl Immunol. 89:102199. doi: 10.1016/j.trim.2025.102199
Song, X., Lao, J., Wang, L., and Liu, S. (2024). Research advances on short-chain fatty acids in gastrointestinal acute graft-vs.-host disease. Ther Adv Hematol. 15:20406207241237600. doi: 10.1177/20406207241237602
Stein, R. A., and Riber, L. (2023). Epigenetic effects of short-chain fatty acids from the large intestine on host cells. MicroLife. 4. , doi: 10.1093/femsml/uqad032
Swimm, A., Giver, C. R., DeFilipp, Z., Rangaraju, S., Sharma, A., Ulezko Antonova, A., et al. (2018). Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-vs.-host disease. Blood 132, 2506–2519. doi: 10.1182/blood-2018-03-838193
Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., Macia, L., et al. (2014). The role of short-chain fatty acids in health and disease. Adv Immunol. 121, 91–119. doi: 10.1016/B978-0-12-800100-4.00003-9
Taur, Y., Coyte, K., Schluter, J., Robilotti, E., Figueroa, C., Gjonbalaj, M., et al. (2018). Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci. Transl. Med. 10:eaap9489. doi: 10.1126/scitranslmed.aap9489
Teshima, T., Reddy, P., and Zeiser, R. (2016). Acute graft-vs.-host disease: novel biological insights. Biol. Blood Marrow Transplant 22, 11–16. doi: 10.1016/j.bbmt.2015.10.001
Then, C., Paillas, S., Wang, X., Hampson, A., and Kiltie, A. E. (2020). Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation. BMC Biol. 18:102. doi: 10.1186/s12915-020-00836-x
Thiele Orberg, E., Meedt, E., Hiergeist, A., Heinrich, P., Fan, K., Khalid, O., et al. (2024). Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation. Nat Cancer. 5, 187–208. doi: 10.1038/s43018-023-00669-x
Trunk, A. D., Guo, M., Budvytyte, L., Islam, N., Khera, N., et al. (2024). Hematopoietic stem-cell transplantation: exploring the latest advances and gaps in disparities, psychosocial and symptom management interventions, and chronic graft-vs.-host disease care. Am. Soc. Clin. Oncol. 44:e432186. doi: 10.1200/EDBK_432186
Tyszka, M., Maciejewska-Markiewicz, D., Styburski, D., Biliński, J., Tomaszewska, A., Stachowska, E., et al. (2024). Altered lipid metabolism in patients with acute graft-vs.-host disease after allogeneic hematopoietic cell transplantation. Leuk Res. 137:107435. doi: 10.1016/j.leukres.2024.107435
Vaillant, A. A. J., Modi, P., and Mohammadi, O. (2024). “Graft-Vs.-Host Disease,” in Transplantation of the Pancreas (Treasure Island, FL: StatPearls Publishing), 755–763.
Venkidesh, B. S., Shankar, S. R., Narasimhamurthy, R. K., Rao, S. B. S., and Mumbrekar, K. D. (2023). Radioprotective potential of probiotics against gastrointestinal and neuronal toxicity: a preclinical study. Clin Transl Oncol. 25, 3165–3173. doi: 10.1007/s12094-023-03184-8
Wang, J. C. C., Teichman, J. C., Mustafa, M., O'Donnell, H., Broady, R., Yeung, S. N., et al. (2015). Risk factors for the development of ocular graft-vs.-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. Br. J. Ophthalmol. 99, 1514–1518. doi: 10.1136/bjophthalmol-2014-306438
Wang, P. P., Cheng, X. Q., Dou, Z. J., Fan, Y. Q., Chen, J., Zhao, L., et al. (2024). Inhibiting the CB1 receptor in CIH-induced animal model alleviates colon injury. Appl Microbiol Biotechnol. 108 doi: 10.1007/s00253-024-13216-0
Wu, J., Huang, H., Wang, L., Gao, M., Meng, S., Zou, S., et al. (2023). A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation. Gut Microbes. 16:2316575. doi: 10.1080/19490976.2024.2316575
Yazdandoust, E., Hajifathali, A., Roshandel, E., Zarif, M. N., Pourfathollah, A. A., Parkhideh, S., et al. (2023). Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 78:101836. doi: 10.1016/j.trim.2023.101836
Yoo, J. Y., Groer, M., Dutra, S. V. O., Sarkar, A., and McSkimming, D. I. (2020). Gut microbiota and immune system interactions. Microorganisms. 8:1587. doi: 10.3390/microorganisms8101587
Yoon, M. Y., and Yoon, S. S. (2018). Disruption of the gut ecosystem by antibiotics. Yonsei Med. J. 59, 4–12. doi: 10.3349/ymj.2018.59.1.4
Yue, X. Y., Zhou, H., Wang, S. F., Chen, X., and Xiao, H. W. (2024). Gut microbiota, microbiota-derived metabolites, and graft-vs.-host disease. Cancer Med. 13:e6799. doi: 10.1002/cam4.6799
Zama, D., Biagi, E., Masetti, R., Gasperini, P., Prete, A., Candela, M.s, et al. (2017). Gut microbiota and hematopoietic stem cell transplantation: where do we stand? Bone Marrow Transplant. 52, 7–14. doi: 10.1038/bmt.2016.173
Zeiser, R., and Blazar, B. R. (2017). Pathophysiology of chronic graft-vs.-host disease and therapeutic targets. New Engl. J. Med. 377, 2565–2579. doi: 10.1056/NEJMra1703472
Zhang, D., Jian, Y. P., Zhang, Y. N., Li, Y., Gu, L. T., Sun, H. H., et al. (2023a). Short-chain fatty acids in diseases. Cell Commun. Signal. 21, 1–20. doi: 10.1186/s12964-023-01219-9
Zhang, Y., Pan, J., Liu, Y., Zhang, X., and Cheng, K. (2023b). Effects of ficus pandurata hance var. angustifolia cheng flavonoids on intestinal barrier and cognitive function by regulating intestinal microbiota. Foods 12:1682. doi: 10.3390/foods12081682
Zhao, T. S., Xie, L. W., Cai, S., Xu, J. Y., Zhou, H., and Tang, L. F. (2021), Dysbiosis of gut microbiota is associated with the progression of radiation-induced intestinal injury is alleviated by oral compound probiotics in mouse model. Front. Cell Infect Microbiol. 11:717636. doi: 10.3389/fcimb.2021.717636.
Keywords: butyrate, epigenetic regulation, graft-vs.-host disease (GvHD), gut microbiota, gut-immune axis, hematopoietic stem cell transplantation (HSCT), intestinal barrier, short-chain fatty acids (SCFAs)
Citation: Hajjar C, Kuijper EJ, Butel M-J, Khoury G, Mallah M, Karam Sarkis D, Lesnik P, Le Goff W, Bazarbachi A and Abifadel M (2026) Microbiota-derived short-chain fatty acids in hematopoietic stem cell transplantation: immunomodulation at the host-microbiota interface. Front. Microbiol. 17:1754099. doi: 10.3389/fmicb.2026.1754099
Received: 25 November 2025; Revised: 31 December 2025;
Accepted: 05 January 2026; Published: 06 February 2026.
Edited by:
Yu Pi, Chinese Academy of Agricultural Sciences, ChinaReviewed by:
Lijie Han, First Affiliated Hospital of Zhengzhou University, ChinaTakahide Ara, Hokkaido University Faculty of Medicine, Japan
Copyright © 2026 Hajjar, Kuijper, Butel, Khoury, Mallah, Karam Sarkis, Lesnik, Le Goff, Bazarbachi and Abifadel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Crystel Hajjar, Y3J5c3RlbC5oYWpqYXIxQHVzai5lZHUubGI=
†Deceased